Literature DB >> 21280052

Application of a high-throughput screening procedure with PEG-induced precipitation to compare relative protein solubility during formulation development with IgG1 monoclonal antibodies.

Todd J Gibson1, Katie Mccarty, Iain J Mcfadyen, Ethan Cash, Paul Dalmonte, Kenneth D Hinds, Adam A Dinerman, Juan C Alvarez, David B Volkin.   

Abstract

Protein solubility is a critical attribute in monoclonal antibody (mAb) formulation development as insolubility issues can negatively impact drug stability, activity, bioavailability, and immunogenicity. A high-throughput adaptation of an experimental method previously established in the literature to determine apparent protein solubility is described, where polyethylene glycol (PEG) is used to reduce protein solubility in a quantitatively definable manner. Utilizing an automated, high-throughput system, an immunoglobulin G (IgG)1 mAb in a variety of buffer conditions was exposed to increasing concentrations of PEG and the amount of protein remaining in solution was determined. Comparisons of PEG(midpt) values (the weight% PEG in solution required to decrease the protein concentration by 50%) to extrapolated values of apparent protein solubility (in the absence of PEG) were performed. The determination of PEG(midpt) by using sigmoidal curve fitting of the entire data set was shown to be the most precise and reproducible approach for use during high-throughput screening experiments. The high-throughput PEG methodology was then applied to the screening of different formulations to optimize relative protein solubility profiles (weight% PEG vs. protein concentration and their corresponding PEG(midpt) values) in terms of solution pH and buffer ions for both human and chimeric IgG1 mAbs. Other comparisons included evaluating relative solubility profiles of an IgG1 mAb produced from different cell lines (Chinese hamster ovary vs. murine) as well as for different IgG1 mAbs (produced from the same cell line) in a series of formulation buffers. Based on these comparisons, it was concluded that rapid, high-throughput determinations of relative protein solubility profiles can be used as a practical, experimental tool to compare mAb preparations and to rank order buffer and pH conditions during formulation development.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21280052     DOI: 10.1002/jps.22350

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  21 in total

1.  High-throughput analysis of concentration-dependent antibody self-association.

Authors:  Shantanu V Sule; Muppalla Sukumar; William F Weiss; Anna Marie Marcelino-Cruz; Tyler Sample; Peter M Tessier
Journal:  Biophys J       Date:  2011-10-05       Impact factor: 4.033

Review 2.  High-throughput biophysical analysis of protein therapeutics to examine interrelationships between aggregate formation and conformational stability.

Authors:  Rajoshi Chaudhuri; Yuan Cheng; C Russell Middaugh; David B Volkin
Journal:  AAPS J       Date:  2013-10-31       Impact factor: 4.009

Review 3.  Structure, heterogeneity and developability assessment of therapeutic antibodies.

Authors:  Yingda Xu; Dongdong Wang; Bruce Mason; Tony Rossomando; Ning Li; Dingjiang Liu; Jason K Cheung; Wei Xu; Smita Raghava; Amit Katiyar; Christine Nowak; Tao Xiang; Diane D Dong; Joanne Sun; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-12-17       Impact factor: 5.857

4.  Isotonic concentrations of excipients control the dimerization rate of a therapeutic immunoglobulin G1 antibody during refrigerated storage based on their rank order of native-state interaction.

Authors:  Douglas D Banks; Jon F Cordia; Vladimir Spasojevic; Jeonghoon Sun; Sarah Franc; Younhee Cho
Journal:  Protein Sci       Date:  2018-12       Impact factor: 6.725

5.  Probing structurally altered and aggregated states of therapeutically relevant proteins using GroEL coupled to bio-layer interferometry.

Authors:  Subhashchandra Naik; Ozan S Kumru; Melissa Cullom; Srivalli N Telikepalli; Elizabeth Lindboe; Taylor L Roop; Sangeeta B Joshi; Divya Amin; Phillip Gao; C Russell Middaugh; David B Volkin; Mark T Fisher
Journal:  Protein Sci       Date:  2014-07-28       Impact factor: 6.725

Review 6.  Multidimensional methods for the formulation of biopharmaceuticals and vaccines.

Authors:  Nathaniel R Maddux; Sangeeta B Joshi; David B Volkin; John P Ralston; C Russell Middaugh
Journal:  J Pharm Sci       Date:  2011-06-06       Impact factor: 3.534

7.  PDADMAC flocculation of Chinese hamster ovary cells: enabling a centrifuge-less harvest process for monoclonal antibodies.

Authors:  Thomas McNerney; Anne Thomas; Anna Senczuk; Krista Petty; Xiaoyang Zhao; Rob Piper; Juliane Carvalho; Matthew Hammond; Satin Sawant; Jeanine Bussiere
Journal:  MAbs       Date:  2015       Impact factor: 5.857

8.  Development of a high-throughput solubility screening assay for use in antibody discovery.

Authors:  Qing Chai; James Shih; Caroline Weldon; Samantha Phan; Bryan E Jones
Journal:  MAbs       Date:  2019-03-26       Impact factor: 5.857

9.  Mechanisms of precipitate formation during the purification of an Fc-fusion protein.

Authors:  Daniel G Greene; Steven J Traylor; Jing Guo; Leila H Choe; Shannon Modla; Xuankuo Xu; Nripen Singh; Lye Lin Lock; Sanchayita Ghose; Zheng Jian Li; Kelvin H Lee; Norman J Wagner; Abraham M Lenhoff
Journal:  Biotechnol Bioeng       Date:  2018-07-25       Impact factor: 4.530

10.  Assessment of Therapeutic Antibody Developability by Combinations of In Vitro and In Silico Methods.

Authors:  Adriana-Michelle Wolf Pérez; Nikolai Lorenzen; Michele Vendruscolo; Pietro Sormanni
Journal:  Methods Mol Biol       Date:  2022
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.